Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Change in Accured Expenses (2020 - 2025)

Insight Molecular Diagnostics' Change in Accured Expenses history spans 6 years, with the latest figure at $1.2 million for Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 81.36% year-over-year to $1.2 million; the TTM value through Sep 2025 reached -$205000.0, up 31.89%, while the annual FY2024 figure was $967000.0, 120.33% up from the prior year.
  • Change in Accured Expenses for Q3 2025 was $1.2 million at Insight Molecular Diagnostics, up from -$3.1 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.2 million in Q3 2025 and bottomed at -$3.1 million in Q2 2025.
  • The 5-year median for Change in Accured Expenses is $126000.0 (2023), against an average of -$302631.6.
  • The largest annual shift saw Change in Accured Expenses plummeted 12576.19% in 2023 before it skyrocketed 415.08% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $244000.0 in 2021, then plummeted by 151.23% to -$125000.0 in 2022, then plummeted by 351.2% to -$564000.0 in 2023, then skyrocketed by 224.82% to $704000.0 in 2024, then surged by 67.19% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Change in Accured Expenses are $1.2 million (Q3 2025), -$3.1 million (Q2 2025), and $1.0 million (Q1 2025).